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Abstract
Background: Hyaluronan (HA) is made at the plasma membrane and secreted into the extracellular medium or
matrix by phospolipid-dependent hyaluronan synthase (HAS), which is active as a monomer. Since the mechanism
by which HA is translocated across membranes is still unresolved, we assessed the presence of an intraprotein
pore within HAS by adding purified Streptococcus equisimilis HAS (SeHAS) to liposomes preloaded with the
fluorophore Cascade Blue (CB).
Results: CB translocation (efflux) was not observed with mock-purified material from empty vector control E. coli
membranes, but was induced by SeHAS, purified from membranes, in a time- and dose-dependent manner. CB
efflux was eliminated or greatly reduced when purified SeHAS was first treated under conditions that inhibit
enzyme activity: heating, oxidization or cysteine modification with N-ethylmaleimide. Reduced CB efflux also
occurred with SeHAS K48E or K48F mutants, in which alteration of K48 within membrane domain 2 causes
decreased activity and HA product size. The above results used liposomes containing bovine cardiolipin (BCL). An
earlier study testing many synthetic lipids found that the best activating lipid for SeHAS is tetraoleoyl cardiolipin
(TO-CL) and that, in contrast, tetramyristoyl cardiolipin (TM-CL) is an inactivating lipid (Weigel et al, J. Biol. Chem.
281, 36542, 2006). Consistent with the effects of these CL species on SeHAS activity, CB efflux was more than 2-
fold greater in liposomes made with TO-CL compared to TM-CL.
Conclusions: The results indicate the presence of an intraprotein pore in HAS and support a model in which HA is
translocated to the exterior by HAS itself.
Background
Hyaluronic acid (hyaluronan; HA) is a linear
unbranched polysaccharide composed of repeating dis-
accharide units of N-acetyl-glucosamine and D-glucuro-
nic acid. In vertebrates and streptococcal species, HA is
synthesized by Class I HA synthases (HAS), lipid-depen-
dent integral membrane proteins with eight membrane
domains (MDs) in eukaryotes or six MDs in species
such as S. pyogenes and S. equisimilis [1,2]. Mammals
express three HAS isozymes encoded by distinct genes
designated HAS1, HAS2 and HAS3. HA is an essential
glycosaminoglycan in vertebrate extracellular matrices
[3], where it helps maintain the physical structure and
integrity of tissues, in particular cartilage. HA is also a
major constituent of skin, vitreous humor in the eye,
synovial fluid in joints, and the cumulus cell matrix that
surrounds oocytes prior to ovulation. In tissue matrices
or vitreous, HA ranges in molecular mass up to 10 MDa
(25, 000 disaccharide units) and occupies a very large
volume in physiological fluids. In addition to its physical
functions, it is now clear that HA has multiple different
size-dependent functions and is capable of stimulating
intracellular signal transduction to alter gene expression
and cell behavior in angiogenesis, inflammatory diseases,
tumorigenesis and metastasis [4-8].
Two mechanisms have been suggested for how HA is
transferred across the cell membrane to the exterior.
The first [9] is that HAS itself, which is active as a
monomer in complex with multiple lipids molecules
[ 1 0 ] ,m e d i a t e sH At r a n s l o c a t i o nv i aap o r ew i t h i nt h e
multiple MDs of the protein. The second is that a grow-
ing HA chain in the cytoplasm binds to an ABC trans-
porter, which then transfers the chain across the
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of a gene near the S. pyogenes has operon reduced HA
synthesis and secretion by about 65%, although SpHAS
activity in lysed cells was unaffected. The mutated gene
had sequence similarity to bacterial ABC transporter
genes. In eukaryotic cells, the current proposal is that
both the multiple drug resistance protein-5 (MRP5;
ABCC5) and the cystic fibrosis conductance regulator
are ABC transporters that would bind and translocate
intracellular HA to the exterior in an ATP-dependent
manner [13,14].
The HAS Pore model is based on three aspects of
HAS structure and function that are very novel for a
glycosyltransferase: the lipid-dependence, the large num-
ber of MDs, and the processive mechanism of HA
synthesis. Very few glycosyltransferases are multiple
membrane spanning proteins and dependent on lipid for
activity. HA·HAS complexes remain associated for 2-4
hr until the completed MDa HA chains are released
[15]. Additional support for the Pore model is that
insertion of a HAS gene into cells that do not otherwise
make HA can confer the ability to synthesize and
secrete HA in prokaryotes [16,17] or eukaryotes such as
drosophila [18]. These results are readily explained by
the ability of HAS alone to both assemble and translo-
cate HA. The ABC transporter model explains these lat-
ter results by proposing that the transporters in cells
that do not make HA are promiscuous enough to trans-
port not only their normal substrates, but also the large
HA polysaccharide made when a HAS gene is intro-
duced. A further distinction is that in contrast to the
ABC transporter model, the HAS Pore model with
coupled HA synthesis and translocation does not
require ATP.
In this study, we tested a central prediction of the
Pore model, that HAS contains an intraprotein pore, by
assessing the ability of purified SeHAS to mediate efflux
(i.e. translocation) of the small fluorescent dye Cascade
Blue (CB, 538.4 Da) from the inside of pre-loaded lipo-
somes to the external medium. The results indicate that
SeHAS can mediate CB efflux when added to liposomes
and that this pore-like activity is eliminated or impaired
by a range of treatments or conditions that inhibit the
synthase activity of SeHAS.
Results
CB Efflux occurs after SeHAS addition to liposomes
When CB dye is released from liposomes and bound by
anti-CB antibody (Ab) in the external phase (Figure 1),
its fluorescence (FL) is quenched. Luminal CB does not
readily leak through the liposomoal membrane, and
hence, is protected from the quenching. However, CB
release can occur in several ways, including detergent
mediated lysis, loss of liposome integrity (e.g.d u et o
aging-induced lipid oxidation and degradation), or by
passage through pores formed by insertion of proteins
into liposomal membranes [19,20]. For these experi-
ments, SeHAS was purified using a protocol with
reduced n-dodecyl-b-D-maltoside (DDM) and glycerol
concentrations to minimize carryover of any detergent.
Prior to protein addition or in the absence of addition, a
stable FL baseline was observed, indicating that no CB
dye is released spontaneously from liposomes at 30°C.
After SeHAS addition, there was a time-dependent
decrease in FL (an increase in quenching) indicating an
ongoing efflux of CB (Figure 2A). In contrast, there was
no quenching when the same buffer without SeHAS or
when mock-purification material from empty-vector
membranes was added. The latter control indicates that
CB efflux from liposomes was not caused by residual
DDM or other membrane contaminants. Essentially all
of the added SeHAS was incorporated into the lipo-
somes under these conditions (Figure 2B). Additionally,
SeHAS did not cause dye release and quenching when
added to liposomes containing a larger (3 kDa) dextran-
CB conjugate (not shown).
CB efflux from liposomes is dependent on SeHAS
concentration
If CB efflux is mediated by SeHAS insertion into lipo-
somes, this effect should be dose dependent. When this
was assessed using different amounts of purified SeHAS,
the resulting CB efflux was dependent on SeHAS
Step 1
Step 3
Figure 1 Experimental model for monitoring HAS-mediated FL
quenching in liposomes. Step 1 in the scheme depicts the
addition of purified SeHAS (cylinders) to extrusion liposomes (large
circles) containing free CB (small circles). In step 2, HAS molecules
insert into the liposome bilayer, allowing the small CB dye to
translocate (efflux) through the HAS pores to the exterior if an
intraprotein pore is present. In experiments with continuous FL
monitoring in the presence of external anti-CB Ab (black Y), CB that
effluxes from the lumen is bound by Ab resulting in FL quenching
(step 3).
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Page 2 of 9concentration (Figure 3). After adding SeHAS to 50,
100, or 200 nM, the quenching after 30 min was 3%, 6%
and 14%, respectively. Thus, essentially a linear response
in CB efflux was observed with increasing SeHAS con-
centration, consistent with the interpretation that CB
efflux is mediated by, and dependent on, SeHAS.
SeHAS-mediated CB efflux is greater from liposomes
made with an activating compared to an inactivating
lipid
If CB efflux is mediated by native active SeHAS, then
this response should be increased by conditions that sti-
mulate enzyme activity and decreased by treatments
that inhibit or inactivate enzyme activity. SeHAS and
other Class I HAS enzymes are lipid-dependent [1,9,21].
For SeHAS, we found that tetraoleoyl cardiolipin (TO-
CL), containing C18:1 oleoyl groups (with one double
bond), is the best activating phospholipid, whereas tetra-
myrstoyl cardiolipin (TM-CL) with saturated C14:0 myr-
istyl groups actually inhibits SeHAS activity [22]. Earlier
radiation inactivation studies found that active native
and recombinant streptococcal synthases are a complex
of one HAS monomer and ~16 cardiolipin molecules
[10]. The liposomes used here were made with 5%
bovine cardiolipin (BCL), which contains several CL spe-
cies including TO-CL and is an activating lipid for
SeHAS [21].
To determine if CB efflux mediated by SeHAS is influ-
enced by the CL species present, we tested liposomes
made with an E. coli-based lipid composition of phos-
phatidyglycerol (PG) and phosphatidyethanolamine (PE)
and either 5% TO-CL or TM-CL, in place of BCL. The
maximal quenching induced by SeHAS addition to lipo-
somes made with TO-CL was more than 2-fold greater
than in liposomes made with TM-CL (Figure 4). Inter-
estingly, quenching using TM-CL liposomes was ~20%
less compared to the standard liposomes made with
BCL, but quenching in liposomes made with TO-CL
was ~50% greater.
Fluorescence quenching does not occur after addition of
heat-inactivated, oxidized or Cys-modified SeHAS
To determine if the observed CB efflux required active
native SeHAS, we inactivated the enzyme by heating for
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Figure 2 Incorporation of SeHAS into extrusion liposomes
induces CB quenching. A. Extrusion liposomes loaded with CB
were prepared, purified and stored at 4°C under argon as described
in Methods. Liposomes were suspended in 0.25 ml 0.1 M NaCl, 51
mM sodium phosphate, 3.8 mM Na citrate, pH 7.4 (~50 μM PL) with
10 μg/ml anti-CB Ab and equilibrated at 30°C in cuvettes in the
fluorometer. FL was monitored at 433 nm for 5 min to obtain a
stable base-line (time-zero), and then SeHAS (15 μl; purified with no
DDM or glycerol in the elution buffer) was added to 200 nM (black
circles; mean ± SE, n = 3) or the same volume of mock-purified
empty-vector membranes (white circles) or elution buffer (white
squares) was added. Samples were mixed well and FL monitoring
was continued. Decreasing FL (ongoing quenching) was observed
after SeHAS addition, but not after addition of elution buffer or
mock-purified material from empty-vector membranes. B. Purified
SeHAS was added to extrusion liposomes as in A and after 30 min
the suspension was centrifuged, the supernatant was saved, and the
pellet was resuspended and centrifuged. The final pellet (lane 2)
was resuspended to the same volume as the original supernatant
(lane 3), trichloroacetic acid was added (to 10%; w/v) to both
samples and precipitated protein was centrifuged, redissolved in
Laemmli buffer and analyzed by SDS-PAGE and Western blotting
with anti-SeHAS Ab. Lane 1 is a sample of purified SeHAS
precipitated and redissolved in parallel as a control.
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Figure 3 SeHAS-dependent quenching in extrusion liposomes
is concentration dependent. Different amounts of purified SeHAS,
in the same volume of Elution Buffer, were added to CB-containing
liposomes at 30°C to final concentrations of 50 (black squares), 100
(black triangles), or 200 (black circles) nM and FL changes were
recorded as in Fig 2. In this and the following Figs, FL quenching
(1.0 - relative FL) is graphed, rather than relative FL. After 1800
seconds, quenching was 3%, 6%, and 14% in response to addition
of 50, 100 and 200 nM SeHAS, respectively.
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Page 3 of 95 min at 47°C [21]. There was no quenching of CB FL
when this inactive SeHAS was added to liposomes (Fig-
ure 5A), indicating that native enzyme is required. It has
been known for > 50 years that HA synthesis does not
occur if the enzyme is oxidized; thus, a reducing agent
is required to maintain enzyme activity [23]. To assess
the ability of oxidized SeHAS to mediate CB efflux, we
omitted DTT during the standard elution step, which
resulted in inactive enzyme (not shown) that was unable
to mediate CB efflux from liposomes (Figure 5B). Redu-
cing the oxidized SeHAS by adding back DTT recovered
both enzymatic activity and the ability to mediate CB
efflux. Although Cys residues in SeHAS or SpHAS are
not required for enzyme activity, their modification by
NEM or other sulfhydryl reagents drastically reduces
activity [24-26]. Adding SeHAS pretreated with NEM to
liposomes resulted in ~75% less quenching compared to
unmodified enzyme, whereas addition of NEM alone did
not quench CB FL (Figure 5C). Thus, three different
treatments that inhibit HAS activity also decreased the
ability of SeHAS to mediate CB efflux.
CB efflux from liposomes is reduced in SeHAS MD
mutants
We reported previously that two charged residues
within MD2 (Lys
48)a n dM D 4( G l u
328) appear to act
together (e.g. as an ion pair) to stabilize the protein and
allow synthesis of very large HA [27]. These two MD
residues are within the proposed intraprotein pore of
HAS. The Vmax of SeHAS(K48E), a charge-switch
mutant, is reduced by 93% and it makes HA that is 81%
smaller compared to WT SeHAS. CB quenching after
addition of SeHAS(K48E) to liposomes was reduced by
66% compared to WT (Figure 6A). We also tested a
K48F variant because the replacement residue has a
bulky side group and this mutant makes HA that is
~77% smaller than WT. FL quenching was reduced by
~45% compared to addition of WT SeHAS (Figure 6B).
These results indicate that CB efflux mediated by
SeHAS is inhibited by mutations in the putative pore
region that decrease both enzyme activity and HA pro-
duct size.
Discussion
The present results demonstrate that purified HAS
reconstituted into liposomes mediates luminal CB efflux
in a manner consistent with the presence of a HAS
pore. HAS-mediated dye efflux was time-dependent and
HAS concentration-dependent, and efflux did not occur
or was greatly impaired if the enzyme was first inacti-
vated by heat treatment or Cys -SH group modification
by either oxidation or reaction with NEM. These results
indicate that active native enzyme is required for efflux.
HAS enzyme function is greatly affected by whether suf-
ficient activating phospholipid is present. We previously
found that purified SeHAS retains enough tightly bound
endogenous lipid to retain low activity (and not be
denatured), but the enzyme can be activated ≥ 10-fold
by addition of TO-CL, containing C18:1 oleic acid
chains; the best activating lipid identified so far [22]. In
contrast, TM-CL, containing C14:0 saturated fatty acids,
does not activate SeHAS. The finding that HAS-
mediated dye efflux was greater in liposomes with TO-
CL compared to BCL and greater with BCL versus TM-
CL is consistent with the presence of a pore whose size
is dependent on the associated CL species.
An intraprotein pore in HAS-CL complexes may be
smaller or distorted (thus slowing the rate of efflux) in
the presence of the “bad” TM-CL species. Unlike other
phosholipids, CL (also called diphosphatidylglycerol) has
a “double” head group and four fatty acyl chains. Conse-
quently, whereas other lipids occupy roughly cylindrical
volumes, CL is shaped more like a cone with the nar-
rower head group at the top. This structure imparts a
natural tendency for CL to create or to localize to areas
of negative (i.e. concave) membrane curvature [28]. We
conclude that HAS could be activated by TO-CL, which
favors negative curvature in the inner leaflet, because it
would decrease lateral pressure on the protein and thus
open up the cytoplasmic active sites and intraHAS pore
[29]. In contrast, HAS inhibition by TM-CL, whose
shorter unkinked acyl chains favor a more cylindrical
shape and more positive membrane curvature, could
occur because it increases lateral pressure on the protein
and would narrow the pore.
Since cloning and characterizing the first HAS [30],
we have been interested in understanding how HAS
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Figure 4 SeHAS mediates greater CB release from extrusion
liposomes containing activating TO-CL compared to inhibitory
TM-CL. Purified SeHAS was added to liposomes containing (mol%)
70% PE, 25% PG and either 5% TO-CL (black circles) or TM-CL (black
triangles). Subsequent release of CB and FL quenching by anti-CB Ab
was monitored as described in Fig 2. Values are the mean ± SE (n =
3). Note that the FL quenching scale is greater than in other Figs.
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Page 4 of 9regulates the size of HA chains it assembles and how
HA·HAS complexes can stay together for hours without
dissociating during continuous polymerization of a
growing chain at the reducing end (unlike the vast
majority of glycosyltransferases that act at the nonredu-
cing end). The characteristics of the HAS protein itself
and how it functions led us to propose the Pore model
for HA translocation through and by a HAS-lipid com-
plex [1,9,31]. For example, the lipid-dependence and 6-8
MDs of membrane-bound HAS enzymes are character-
istics common to pore forming proteins [19,32-35].
Additionally, the substrate binding sites are on the
cytoplasmic side of the protein close to the cytoplasm-
membrane interface [2,26] and the enzyme is highly
processive [15,36].
Processive biosynthesis requires that after each cataly-
tic cycle the HA-UDP product must transiently dissoci-
ate, without being released to diffusion, move relative to
the enzyme active sites, and then rebind to HAS for the
next cycle of sugar additions. As with other polymerases,
the binding interaction between enzyme and polymer
substrate cannot be of such high affinity that the rate of
release, and thus rebinding of polymer, is too slow.
Many RNA and DNA enzymes (e.g. polymerases and
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Figure 5 SeHAS inactivated by heat, oxidation or NEM modification does not mediate CB release from extrusion liposomes.A .H e a t
inactivation. CB-containing liposomes were treated at 30°C as in Fig 2 except that before addition to liposomes, purified SeHAS was either
treated at 47°C for 5 min to inactivate the enzyme (black triangles) or left untreated on ice (black circles). FL quenching was monitored as in Fig
2. B. Oxidative inactivation. Purified oxidized SeHAS was prepared by omitting DTT in the elution buffer. Oxidized SeHAS was then either left
oxidized (black triangles) or was reduced by treatment with 1 mM DTT for 1 hr at 4°C (black circles) and then added to extrusion liposomes and
FL quenching monitored as in Fig 2. The response with reduced and rescued SeHAS is essentially identical to the untreated enzyme in A. C.
NEM modification. Purified SeHAS was untreated (black circles) or treated (black triangles) for 15 min at 4°C with 6 mM NEM, which inhibits
SeHAS activity (24); DTT (12 mM) was then added to react with the remaining NEM. SeHAS was added to CB-liposomes to a final concentration
of 200 nM and FL changes were monitored as in Fig 2. CB-liposomes without SeHAS were also incubated in the same way with NEM and DTT
as a control (black squares) to assess possible leakage.
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Figure 6 K48E and K48F mutants mediate less CB release from liposomes than WT SeHAS. Purified WT (black circles) and K48E (Panel A,
black squares) or K48F (Panel B, black squares) SeHAS were added to CB-containing liposomes and FL quenching was monitored at 30°C for the
indicated times as in Fig. 2.
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by creating topological or spatial constraints so that
enzyme and product cannot dissociate. Molecular
tethering strategies include formation of either multi-
protein complexes that surround and encase the poly-
meric substrate or an intra-enzyme channel or pore to
achieve a similar entrapment of the polymer.
This processivity of HA·HAS complexes is most con-
sistent with the Pore model, which provides a topologi-
cal mechanism to prevent dissociation during HA
elongation. Since the 6-8 MDs of HAS enzymes are
associated with multiple lipid molecules, it seems most
likely that they utilize an intraHAS pore or deep cleft
within the membrane that simultaneously serves to
topologically constrain and also to provide a transloca-
tion mechanism to move the growing chain to the cell
exterior. When dissociation does occur, HA release
appears to terminate further elongation, perhaps due to
loss of UDP at the reducing end - a chain terminating
event. Even high affinity interactions (e.g. between
receptors and ligands) typically have nM Kd values and
measurable off-rates. The extremely slow, essentially
immeasurable, off-rate for HA·HAS complex dissocia-
tion is inconsistent with enzyme reactions that use solu-
ble substrates, which typically have Km values in the μM
range, as proposed in the ABC transport model.
We previously identified Lys
48 and Glu
327 in MD2 and
MD4, respectively, as important residues for the ability
of SeHAS to produce large MDa HA [27]; the K48E and
K48F mutants make much smaller HA than WT. The
interpretation that these two residues are within the
proposed HAS pore and may interact with each other
or with the growing HA chain during translocation is
supported by the present findings that CB efflux
mediated by both proteins is decreased compared to
WT.
Since the present evidence supports the presence of an
intraHAS pore through which HA could be translocated
across membranes, it is reasonable to consider alterna-
tive interpretations that could account for reduced HA
synthesis and secretion by inhibition of ABC transpor-
ters, such as MRP5. Two other explanations for
decreased HA synthesis and secretion after inhibition or
knockdown of MRP5 and other ABC transporters are
related to the ability of these proteins to transport
nucleotides (e.g. cGMP, cAMP) as well as nucleotide-
based drugs such as 5’-Fluoro-UMP, a metabolite of the
anticancer drug 5’-Fluorouracil [37]. The first possibility
is that HAS inhibition could be caused by perturbation
of the normal cellular metabolism of uracil-containing
nucleotides, resulting in altered UDP-sugar concentra-
tions or ability of precursor pathways to sustain the
metabolic flux needed to make large amounts of HA. In
eukaryotes, UDP-sugars are synthesized in the cytoplasm
and levels are controlled by several mechanisms, includ-
ing the Golgi anti-port system in which a UDP-sugar is
transported in, while UMP is transported out. UMP
deficiency causes the metabolic disorder orotic aciduria,
but excess UMP (which leads to excess UDP) would
also have a detrimental effect on HA synthesis. UDP is
a potent substrate inhibitor of all Class I HASs [1] and,
in fact, can be used to quench HA synthase activity [15].
Thus, deficiency or inhibition of MRP5 could lead to
accumulation of cytoplasmic UDP and inhibition of
HAS, an indirect result of MRP5 function unrelated to
HA translocation. Both of the above possible indirect
effects on HAS activity would be reversed by lysing cells
(i.e. dilution and mass action effects) and performing
assays with UDP-sugars added in vitro. Although these
and other alternate explanations remain to be tested,
T h o m a sa n dB r o w nr e c e n t l yf o u n dt h a tA B Ct r a n s p o r -
ters are not involved in HA export by cancer cells [38].
Conclusions
We conclude that HAS contains an intraprotein pore
capable of allowing small molecules such as Cascade
Blue (538.4 Da) to pass across liposomal membranes.
Such a pore within HAS provides both an explanation
for the extreme processive behaviour of HAS·HA com-
plexes, which remain associated for hours during bio-
synthesis of MDa HA chains, and a mechanism for the
translocation of HA across cell membranes to the cell
exterior that is consistent with the enzyme’ss t r u c t u r e
and lipid dependence.
Methods
Materials and Buffers
Media components were from Difco (Fisher Scientific).
Plasmid pKK223-3 was from GE Healthcare and E. coli,
SURE™ cells were from Stratagene (La Jolla, CA). Ni
2
+-nitrilotriacetic acid (Ni-NTA) resin was from Qiagen
Inc (Hilden, Germany). CB (8-methoxypyrene-1, 3, 6-tri-
sulfonic acid, trisodium salt, 538.4 Da) and anti-CB
quenching antibody Ab were from Invitrogen-Molecular
Probes. Synthetic TO-CL and TM-CL were from Avanti
Polar Lipids (Alabaster, Alabama). BCL, E. coli PE, and
chicken egg PG were from either Avanti or Sigma-
Aldrich. Other reagents were from Sigma-Aldrich (St.
Louis, MO). Liposome Buffer contains 100 mM NaCl,
51 mM Na2HPO4, 3.8 mM citric acid, pH 7.4. Extrac-
tion Buffer contains 10 mM DDM, 50 mM sodium and
potassium phosphate, pH 7.0, 150 mM NaCl, 10 mM
MgCl2,1 . 0m Mb-mercaptoethanol, 20% glycerol, 0.5
μg/ml leupeptin, 0.7 μg/ml pepstatin, and 46 μg/ml phe-
nylmethylsulfonyl fluoride. Wash and Elution Buffers
contain the same components except that in Wash Buf-
fer glycerol is 10% and DDM is 1 mM, and Elution Buf-
fer does not contain either glycerol or DDM.
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The HAS open reading frame from S. equisimilis, with a
C-terminal His6 fusion, was inserted into the pKK223-3
v e c t o ra n dc l o n e di n t oE. coli SURE-2 cells [17], and
cell growth, lysozyme/EDTA treatment, and membrane
preparation in the presence of protease inhibitors were
performed as described previously [9,21]. Final mem-
brane pellets were stored at -80°C.
Enzyme extraction and purification
In order to minimize the residual detergent associated
with purified SeHAS to be used with liposomes, the
Extraction, Wash and Elution buffers used in previous
purification schemes were modified, as noted above, to
reduce or eliminate glycerol and DDM. Thawed mem-
brane pellets were solubilized in 10 ml of Extraction Buf-
fer for 2 h at 4°C with gentle mixing in a Micromixer E-
36 (Taitec), followed by centrifugation at 100, 000 × g for
1 h at 4°C to sediment insoluble components. Imidazole
was added to the supernatant to a final concentration of
30 mM to minimize nonspecific binding of E. coli pro-
teins and the extract was incubated for 30 min at 4°C
with constant mixing with Ni
2+-depleted NTA resin (0.3
ml in a mini-spin column; Bio-Rad) equilibrated with
Extraction Buffer without MgCl2. The enzyme extract
was removed and then incubated with 0.3 ml Ni
2+-NTA
resin for 2 h at 4°C with constant mixing. After allowing
the resin to pack, unbound proteins were allowed to flow
through, the resin was washed with 10 volumes of Wash
Buffer to remove contaminants, and bound SeHAS was
recovered with 0.3 ml Elution Buffer. SeHAS protein was
determined with the Coomassie protein assay reagent
(Pierce) using bovine serum albumin as the standard, and
purity was assessed by SDS-PAGE; preparations were
typically > 98% pure based on densitometric analysis of
Coomassie-stained gels.
Extrusion liposomes
Liposomes containing CB were prepared as described by
Szoka et al [39,40]. Since recombinant SeHAS in E. coli
membranes has been well characterized and is very
active, we prepared liposomes (unless noted otherwise
in particular experiments) using a phospholipid mixture
based on E. coli membranes: 75% PG, 20% PE and 5%
CL (in mole percents). To facilitate binding between
liposomes and the C-terminal His6 of SeHAS [40], we
also added 1% of a NTA-Ni
2+ PG analogue (Avanti): 1,
2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)
iminodiacetic acid)-succinyl] (nickel salt). Lipids in
chloroform or ethanol were mixed and dried under a
partial vacuum for 3 h at 37°C in a N2 atmosphere. To
the dried lipid mixture was added 0.55 ml of Liposome
Buffer and 30 μM CB [19]. The mixture was incubated
at 37°C for 30 min, and then resuspended by vortex
mixing for 5 min. The lipid mixture was frozen in liquid
N2 and thawed in a 37°C water bath five times to reduce
the content of multilamellar liposomes and to increase
liposome luminal volume, and then passed 21 times
through a 0.2 μm pore size polycarbonate filter at room
temperature using a Lipofast extruder (Avestin Inc,
Ottawa, Canada) to make unilamellar liposomes [39].
Liposomes were stored at 4°C until use, and then exter-
nal CB was removed from liposomes (containing inter-
nal CB) by either centrifugation or size exclusion
chromatography (SEC) over Sephadex G-25.
Monitoring CB release from Extrusion liposomes
CB-loaded liposomes (50 μM phospholipid) were equili-
brated in 0.250 ml Liposome Buffer containing 6-10 μg/
ml anti-CB Ab at 30°C in a cuvette in an SLM-8100
spectrofluorometer [19]. Gentle mixing was achieved
with a flea magnet and magnetic stirrer. FL intensity
was measured (excitation at 405 nm and emission at
433 nm) for at least 5 min until a steady baseline was
achieved. CB release from liposomes, upon addition of
SeHAS or other agents, was monitored continuously by
measuring CB FL in the presence of external anti-CB
Ab that quenches FL. Purified SeHAS (0.83 μM) was
then added to the cuvette to a concentration of 50 nM,
the contents mixed, and continuous FL monitoring
resumed 20 s after SeHAS addition (this time point is
designated as to or 0 sec in Figures 2, 3, 4, 5, and 6). At
the end of each kinetic run, Triton-X100 was added to a
final concentration of 0.1% (v/v) to lyse liposomes, com-
pletely release CB, and obtain values for maximum
(100%) quenching by the anti-CB Ab. Relative FL is cal-
culated as [(Ft-FT)/(Ft0-FT)] where: Ft0 = FL at time-zero
with anti-CB Ab present, but before SeHAS addition to
liposomes; Ft =F La tag i v e nt i m et ,a n dF T is the final
FL 5 min after adding Triton-X100. FL quenching (Q) is
calculated as: Q = (Ft0 -F t)/(Ft0 -F T). Thus, at any
given time Q represents the efflux and quenching of CB
as a fraction of the total FL quenching of CB after Tri-
ton X-100 addition. Q ranges from a value of 0 at t0 to
1.0 after Triton addition.
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